Rossmore Private Capital Has $4.66 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Rossmore Private Capital trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,825 shares of the company’s stock after selling 504 shares during the quarter. Rossmore Private Capital’s holdings in AstraZeneca were worth $4,661,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Martin Investment Management LLC raised its stake in shares of AstraZeneca by 2.8% in the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after acquiring an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC increased its position in AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares during the period. Creative Planning lifted its position in AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after purchasing an additional 16,692 shares during the period. TD Asset Management Inc lifted its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock valued at $104,160,000 after purchasing an additional 121,876 shares during the period. Finally, Northcape Wealth Management LLC bought a new position in shares of AstraZeneca in the 2nd quarter worth $269,000. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the subject of several analyst reports. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $65.19 on Wednesday. The firm has a market cap of $202.13 billion, a PE ratio of 31.49, a P/E/G ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company’s fifty day simple moving average is $76.20 and its 200-day simple moving average is $78.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.